Karen L. Reckamp, MD, on Ramucirumab Plus Pembrolizumab for NSCLC: Practical Clinical Considerations

Posted: Friday, July 8, 2022

Karen L. Reckamp, MD, of Cedars-Sinai Medical Center, discusses findings from the Lung-MAP protocol, which showed that ramucirumab and pembrolizumab improved overall survival in patients with advanced non–small cell lung cancer (NSCLC) who were previously treated with immunotherapy and platinum-based chemotherapy. Among the topics Dr. Reckamp focuses on are the discordance between overall response rate and progression-free survival results vs overall survival; PD-L1 status; and toxicity.